Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy (SWIPE)

Next Previous
Trial Profile

A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy (SWIPE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms SWIPE

Most Recent Events

  • 07 Aug 2024 Planned End Date changed from 31 Dec 2023 to 31 Jan 2025.
  • 07 Aug 2024 Planned primary completion date changed from 31 Oct 2023 to 3 Jan 2025.
  • 22 Sep 2023 Last checked against European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top